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T�e immunopat�ological role of antibodies remains 
poorly understood until t�e relevant autoantigen and 
t�e exogenous immunogen are unknown. Normal 
individuals as well as individuals wit� autoimmune 
diseases and cancer produce antibodies reacting wit� 
a variety of carbo�ydrate determinants [�]. Human 
natural anticarbo�ydrate antibodies belong mostly 
to t�e Ig�-class and t�eir individual p�ysiological 
level is sustained by immune �omeostasis. In some 
patients wit� cancer�� t�e unusually �ig� levels of t�e 
IgG antibody to t�e mucin-type carbo�ydrate epitopes 
were found [�]. T�is may be explained by an adap-
tive immune response indicating an antibody class 
switc�ing to IgG and undergoing affinity maturation. 
As a rule�� t�e serum IgG antibodies affinity-purified on 
synt�etic sorbents ex�ibited a low specificity to tumor-
associated mucins�� possibly due to t�e presence of a 
clustered form of carbo�ydrates in mucins [3�� 4]. As in 
immunoassays or t�e purification of antibodies poly-
acrylamide �PAA��-glycoconjugates wit� a low epitope 
density ������ mol. %�� were used�� t�e specificity of 
t�e antibodies examined may be directed to glycolipids 
�natural targets wit� non-clustered sacc�arides��.
PAA-glycoconjugates are �omogenous antigens 
wit� a single reiterative epitope t�at enables t�e detec-
tion of epitope-specific antibodies [5]. In immunoas-
says�� synt�etic glycoconjugate-models �ave certain 
advantages over natural antigens containing usually 
different determinants. T�e �ig� reproducibility of anti-
body detection by t�e ELISA and t�e low background in 
t�e control make PAA-conjugates a promising tool for 
comparative investigations [��� �]. T�e measurement 
of antibodies to glycolipids is tec�nically demanding 
and different laboratories �ave demonstrated t�at 
t�e immunoassays varied widely in sensitivity and t�e 
criteria employed for a positive test [��].
Taking into consideration t�e �ig� frequency of �u-
man antibodies to glycolipids and t�eir possible role in 
t�e pat�ogenesis of cancer [8]�� we tested t�e serum of 
patients by t�e ELISA using a set of PAA-β-glycocon-
jugates�� and found two populations of IgG antibodies 
t�at were specific to GalNAcβ and GalNAcβ�-3GalNAcβ 
ligands [3] �t�e latter is an outer disacc�aride of Para — 
Forssman glycolipid�� PFdi��. T�e aim of t�e present study 
was to evaluate w�et�er serum antibody levels are re-
lated to t�e progression of gastrointestinal cancer and 
t�e �istopat�ological grading. T�e level of anti-PFdi IgG 
was found to be associated wit� t�e advanced cancer 
and t�at of anti-GalNAcβ IgG was associated wit� t�e 
�istopat�ological grading.
MATERIALS AND METHODS
Subjects. T�e investigation was carried out in ac-
cordance wit� t�e ICH GCP Standards and approved 
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by Tallinn �edical Researc� Et�ics Committee. T�e 
informed consent from t�e subjects under study was 
obtained. Blood transfusion donors and patients wit� 
gastric�� colon or rectal cancer wit� a verified diagnosis 
��istology and tumor staging by t�e pTN� system�� were 
examined [�]. T�e median age of donors was 5� years 
�range 3� to �5 years��; t�at of gastric cancer patients�� 
5� years �range �8 to ��4 years��; and of colorectal cancer 
patients�� �� years �range 4� to ��5 years��. In all cases�� 
except special investigations �t�e effect of a surgical 
removal of t�e tumor or t�e follow-up study���� blood 
samples were taken before t�e surgical operation. T�e 
gastrectomy and extended D� limp�adenectomy�� but 
not spleenectomy�� for gastric cancer and t�e resection 
of local lesions for colorectal cancer were performed. 
T�e patients w�o received c�emo- or X-ray-t�erapy 
were excluded from t�e study. Concomitant diseases 
in patients were examined based on t�e �istory of t�e 
disease and a personal conversation.
Glycoconjugates. T�e glycoconjugates wit� 
polyacrylet�anolamide �PAA�� — GalNAcβ-PAA and 
GalNAcβ�-3GalNAcβ-PAA were received from Lec-
tinity�� Russia. T�e epitope density was �� mol. %. 
Tris��ydroxymet�yl��aminomet�ane-PAA �Tris-PAA�� 
was used as a negative control. 
The determination of epitope-specific antibody 
levels in sera. T�e venous blood serum was kept at 
���� °C. In t�e ELISA�� t�e serum frozen/t�awed once 
was used. T�e met�od was performed as described 
in [�]. Briefly�� PAA-glycoconjugates �5 µg/ml�� in �.�5 
� carbonate buffer�� pH �.��� were applied to t�e Nunc-
Immuno plate ��axiSorp�� and �eld overnig�t at 4 °C. 
After was�ing wit� Tris-buffer/�.�5% Tween-�� �TBS���� 
t�e serum diluted to �:�5��:4�� in TBS/�.�5% casein/
5 m� EDTA-disodium salt was added. T�e dilution of 
sera wit� a buffer containing 5 m� EDTA reduces t�e 
background significantly�� but influences weakly t�e 
specific antibody binding [�]. After incubation for 3 � 
at �� °C�� t�e plate was was�ed and incubated wit� t�e 
goat anti-�uman IgG-alkaline p�osp�atase conjugate 
for �.5 � at �� °C. T�e absorbance �A�� at 4�5 nm of 
t�e reaction wit� a p-nitrop�enylp�osp�ate disodium 
salt �� mg/ml in t�e glycine-buffer�� pH ��.3�� �� °C�� 
� ��� was measured using a Labsystem �ultiscan 
�CC/34� �Finland��. T�e ratio of t�e mean Atest/Acontrol 
was calculated�� w�ere Atest is t�e absorbance wit� t�e 
PAA-glycoconjugate and Acontrol�� wit� t�e Tris-PAA. T�e 
variation coefficient was 3%. 
Clinical analysis of blood samples. T�e bioc�emi-
cal and �aematological analyses were performed in 
Nort�-Estonian Regional Hospital Oncological Centre 
using automatic equipment: a Hitac�i ��� and Elecsys 
������ Roc�e Diagnostics; Sysmex XE-������ Sysmex 
Corporation. Blood samples were taken from patients 
before and/or after a surgical operation during t�e 
planned visits to t�e p�ysician for �ealt� control. T�e 
antibody levels were correlated wit� t�e levels of t�e 
C-reactive protein �CRP���� tumor markers �CA��-��� 
CEA���� alanine aminotransferase�� glucose�� �aemo-
globin�� circulating red blood cells �count���� leukocytes 
�count���� neutrop�ils �%���� monocytes �%���� lymp�ocytes 
�%���� platelets �count�� and eosinop�ils �%��. T�e CRP 
concentration was determined by using a turbidimetri-
cal met�od and tumor markers by an electroc�emilu-
minescense immunoassay.
Statistical methods. T�e �ann — W�itney U-test�� 
�D Cartesian box plots grap� and regression analysis 
were used in t�e study. T�e differences were con-
sidered significant w�en P < �.�5. T�e grap�s were 
plotted by means of a SigmaPlot ���� program and 
Statgrap�ics Plus 5.�.
RESULTS
The relation of antibody levels to cancer. T�e 
subjects were analysed by age�� gender and AB��H�� 
blood group p�enotype to assess t�e possible influen-
ce of t�ese parameters in t�e comparative study. In 
donors as well as in patients wit� cancer t�e levels of 
anti-GalNAcβ and -PFdi IgG antibodies were not related 
to age and gender. T�e relation between antibody le-
vels and t�e blood group p�enotype in donors was not 
observed eit�er. T�e �ig�er anti-PFdi IgG levels for t�e 
A-blood group as compared to t�ose for B or � groups 
were revealed in cancer patients �P = �.�3��. T�erefore�� 
t�e influence of t�e blood group was taken into account: 
an approximately equal ratio of A/B and A/� was c�osen 
for t�e comparison of cancer patients wit� donors as 
well as for analysis by stage of cancer.
Hig� levels of antibodies�� particularly anti-PFdi 
IgG�� were found in t�e serum of patients wit� cancer 
�Fig. ���. T�e anti-PFdi antibody level was significantly 
�ig�er in patients wit� gastrointestinal cancer�� espe-
cially in stages II�IV�� t�an in donors�� w�ereas t�e diffe-
rence in t�e level of anti-GalNAcβ IgG was insignificant 
�Table ���. An asymmetrical distribution of anti-PFdi IgG 
values was c�aracteristic of more advanced cancer 
�Fig. ��� boxes ��� 3 and 4��. T�e median values in stage I 
of gastric cancer were very close to t�ose in donors 
�Table ��� ����� but t�e median in stages II and IV was 
significantly �ig�er �Table ���. Taken toget�er�� stages 
I and II were analyzed for tumor size: t�e differences 
in T� vs T� + T3 remained significant. A similar stage-
dependent c�ange of median values was observed 
for colorectal cancer but differences were significant 
only between stages I and II: P = �.�4�� �tumor size 
status in stage I was T� + T� vs T3 + T4 in stage II��. 
T�e level of anti-GalNAcβ IgG was not related to t�e 
stage of gastric or colorectal cancer. T�ese results and 
our previous data [��] s�ow t�at t�e levels of serum 
anti-carbo�ydrate antibodies in patients wit� cancer 
are eit�er directly or inversely associated wit� tumor 
progression �PFdi�� TF�� αGal�� or do not depend on it 
�GalNAcβ�� Tn���� �Table 3�� summarized data��.
Table 1. Analysis of serum IgG antibody levels in donors and cancer patients 
Serum Anti-GalNAcβ Anti-PFdin Median P n Median P
Donors 96 1.34 107 1.36
Gastric cancer, all stages
Stages II, III, IV
159 1.37 0.30 160
121
1.61
1.88
0.001
0.0002
Colorectal cancer, all 
Stages II, III, IV
88 1.38 0.17 88
69
1.63
1.72
0.074
0.04
Total cancer, all stages 247 1.37 0.22 248 1.62 0.003
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Table 2. The relation between the anti-PFdi IgG level and the stage and size 
status of the tumor in patients with gastric cancer
Stage, size n Median Comparison, P
I 39 1.38 I vs II, 0.029
II 42 1.76 I vs III, 0.056
III 44 1.49 I vs IV, 0.004
IV 35 2.26 III vs IV, 0.065
T1 (I) 31 1.24 T1 vs T2 + T3, 
0.027T2 + T3 (I, II) 50 1.68
Table 3. The association of the serum anticarbohydrate IgG level with the 
progression and histopathological grading of cancer
Antibodies
Tumor progression Histopathological grading*
Gastric can-
cer
Breast cancer Gastrointesti-
nal cancer
Breast cancer
Tn [10] No No No No
GalNAcβ No ND Direct ND
TF [10] Inverse No Direct No
αGal [10] Direct Inverse No Direct
PFdi Direct ND No ND
*Direct association: lower levels are associated with lower-differentiated 
carcinomas (the comparison is shown in Table 4).
ND: not determined.
Fig. 1. Binding of t�e serum IgG-antibody wit� PFdi-PAA ��� 
and GalNAcβ-PAA ��� adsorbed onto immunoplates in patients 
wit� gastric cancer. Lig�t symbols s�ow t�e control binding wit� 
Tris-PAA�� respectively
Fig. 2. T�e distribution of anti-PFdi IgG levels in donors and 
patients. Donors: box No �; gastrointestinal cancer in stage 
I: box No �; gastric cancer in stages II�IV: No 3; colorectal 
cancer in stages II�IV: No 4. T�e lower boundary of t�e box 
indicates t�e �5t� percentile data�� a line wit�in t�e box marks 
t�e median�� and t�e upper boundary of t�e box indicates t�e 
��5t� percentile. Bars above and below t�e box indicate t�e ��t� 
and ��t� percentiles
No relation between t�e levels of anti-GalNAcβ or 
anti-PFdi antibodies and regional lymp� node metasta-
ses �stages II and III�� and distant metastases �stages III 
vs IV�� in patients wit� gastric or colorectal cancer 
was observed. T�e relation between antibody levels 
and t�e �istopat�ological grading was found only for 
anti-GalNAcβ IgG: t�e median for lower-differentiated 
carcinomas was significantly lower �Table 4��.
T�e effect of t�e surgical removal of tumors on anti-
body levels was investigated: blood samples from eac� 
patient were taken before and after surgery at intervals 
of t�ree to sixteen mont�s. T�e postoperative level of 
antibodies was increased in 8����% of patients �av-
ing G3-tumors�� differences were significant. Differen-
ces in pre- vs postoperative levels of anti-GalNAcβ or 
anti-PFdi IgG were not significant for G� + G�-tumors 
�Table 5�� Fig. 3��.
T�e follow-up study of sixty-eig�t patients wit� 
gastrointestinal cancer carried out since ���4 �as 
s�own bot� t�e stimulation and suppression of t�e 
immune response to take place. A long-term �ig� 
anti-PFdi IgG level was also observed but a common 
trend towards t�e decline of antibody levels occurred 
during t�e last period of observation �Fig. 4��.
Fig. 3. Difference in postoperative and preoperative antibody 
levels �∆�� in patients wit� gastrointestinal cancer �stages I�� II�� III��. 
Boxes No � and �: anti-GalNAcβ IgG; No 3 and 4: anti-PFdi IgG. 
Lig�t boxes: patients wit� G� and G� tumors; dark boxes: patients 
wit� G3 tumors. T�e markings are t�e same as s�own in Fig. ��� 
t�e upper bar for t�e last box equals ��.�� �not s�own��
Fig. 4. C�anges of t�e anti-PFdi IgG level during t�e follow-up. 
Patients wit� gastric cancer. T�e zero point s�ows t�e preopera-
tive antibody level.  — stage III�� pT3N���G��3 ;  — II�� pT3N���G� ; 
 — II�� pT3N���G� ;  — II�� pT3N���G3. T�e preoperative antibody 
level was not analysed in t�e last case
Table 4. The relation between the anti-GalNAcβ IgG level and the histo-
pathological grading
Patients Grade n Median Comparison, P
Gastric cancer, all stages
Stages I, II
G1 + G2
G3
G1
G2 + G3
G1 + G2
G3
G1
G2 + G3
59
98
23
134
35
45
17
63
1.58
1.32
1.76
1.35
1.53
1.28
1.95
1.32
G1 + G2 vs G3,
0.010
G1 vs G2 + G3,
0.040
G1 + G2 vs G3,
0.008
G1 vs G2 + G3,
0.022
Colorectal cancer, all stages G1 + G2
G3
62
25
1.39
1.23
G1 + G2 vs G3,
0.04 2
�4 Experimental Oncology ���� ������� ����� ��arc���
Table 5. The effect of the tumor removal on the serum antibody level in 
patients with gastrointestinal cancer
Antibodies Grade n Median of difference* P
GalNAcβ G1 + G2 18 –0.15 0.21
G3 14 0.32 0.009
PFdi G1 + G2 18 0.09 0.77
G3 14 0.46 0.003
*Postoperative minus preoperative antibody level.
The relation of antibody levels to blood parame-
ters and other diseases. T�e anti-PFdi IgG level was 
found to correlate wit� CRP �Fig. 5��. In a follow-up study�� 
anti-GalNAcβ IgG levels correlated wit� t�e monocytes 
percentage �r = �.4��� P = �.����� n = 5���. T�e correlation 
wit� tumor markers and ot�er parameters �see �aterials 
and �et�ods�� was not establis�ed.
Fig. 5. T�e correlation between t�e levels of anti-PFdi IgG and 
CRP. Y = �.���X + �.��4; r = �.5��� P = �.��3�� n = 34
T�e autoimmune and r�eumatic manifestations or 
paraneoplastic syndromes may be observed in pa-
tients wit� malignancies [��]. According to preliminary 
examinations based on t�e �istory of t�e disease and 
a personal conversation�� we did not register diagnoses 
of paraneoplastic neurological disease syndromes�� 
dermatomiositis or systemic lupus eryt�ematosus in 
t�e subgroup of patients wit� a �ig� level of anti-PFdi 
IgG �Atest/Acontrol ≥ ��� dilution �:�5�� n = 54��. Postopera-
tive infectious complications were not related to �ig� 
antibody levels eit�er. Concomitant r�eumatic symp-
toms were marked in �% of patients�� type � diabetes 
in 4% of cases. T�e direct association of t�e levels 
of anti-PFdi antibodies wit� t�e secondary anaemia 
is scarcely probable because t�eir �ig� levels were 
frequently observed in patients wit� a normal count 
of eryt�rocytes. T�e relation of antibodies to ot�er 
diseases will require furt�er study.
DISCUSSION
T�e significantly �ig�er anti-PFdi IgG level in 
patients wit� cancer as compared wit� donors was 
observed. In t�is respect�� t�e anti-PFdi antibodies 
differ from antibodies to ot�er carbo�ydrate antigens 
�TF�� Tn and Forssman�� w�ose level was significantly 
lower in patients wit� gastrointestinal cancer [��� ��]. 
Besides�� for gastric cancer t�e anti-PFdi IgG level was 
significantly �ig�er in stages II�IV t�an in stage I and 
correlated wit� t�e level of CRP. As reported lately�� t�e 
level of CRP was increased in gastric and colorectal 
cancer. T�e increased level of CRP in one-t�ird of 
patients wit� colorectal cancer was associated wit� a 
larger size and advanced stage of t�e tumor [�3�� �4]. 
In t�is respect�� t�e relation of t�e anti-PFdi IgG level to 
tumor progression resembles t�at of an acute-p�ase 
protein CRP. However�� t�e elevation of bot� parame-
ters may be due to different pat�ological conditions 
accompanying tumor progression �inflammation�� 
autoimmunity�� �epatic dysfunction and ot�ers��.
T�e anti-GalNAcβ IgG level was associated wit� t�e 
�istopat�ological grading of gastric and colorectal car-
cinomas �Table 4��. Interestingly�� a similar difference in 
anti-TF for gastrointestinal cancer and in anti-αGal IgG 
for breast cancer was observed earlier as well �Table 3��. 
We �ypot�esized t�at t�e immunosuppression occurs in 
patients wit� low-differentiated carcinoma. T�e effect of 
t�e tumor removal on antibody levels was investigated in 
t�e follow-up. T�e postoperative level of antibodies was 
elevated in patients �aving G3-tumors �Table 5�� Fig. 3��. 
It is notewort�y t�at t�is p�enomenon was observed for 
ot�er anti-carbo�ydrate antibodies �anti-TF�� -Tn and -
αGal IgG�� w�ose postoperative level was increased in a 
majority of patients wit� gastrointestinal low-differentia-
ted carcinomas �a manuscript in preparation��. T�e levels 
of Forssman antibodies in t�e sera of patients �ave been 
reported to be also elevated significantly after a radical 
resection of t�e tumor [���� �5]. T�e total levels of IgG 
and ot�er isotype antibodies remained unc�anged after 
gastrectomy [��]. Taken toget�er�� t�ese results may 
be interpreted as a common suppressive influence of 
carcinomas �low-differentiated mainly�� on t�e produc-
tion of anti-carbo�ydrate antibodies. Alt�oug� t�e 
postoperative elevation of anti-PFdi IgG levels �as well 
as anti-αGal IgG�� unpublis�ed data�� was observed�� t�e 
relation between t�eir levels and �istopat�ological grad-
ing was not registered for gastric and colorectal cancer 
�Table 3��. Per�aps�� t�e direct association of t�e level of 
t�ese antibodies wit� tumor progression does not allow 
a statistical evaluation of t�eir relation to grading. 
T�e terminal β-linked GalNAc residues are specific li-
gands of t�e C-type lectin of �uman macrop�ages�� w�ose 
recognition and targeting modulates immune response 
[���]. We observed t�e correlation of anti-GalNAcβ IgG 
levels wit� t�e percentage of perip�eral blood monocytes 
t�at mig�t reflect t�e adaptive immune response and t�e 
production of specific IgG antibodies.
The putative natural antigens. T�e specificity of t�e 
antibodies examined in t�e ELISA using PAA-conjugates 
wit� a low epitope density may be directed to glycolipids. 
Usually�� an external oligosacc�aride in carbo�ydrate moie-
ty is an immunodominant. Probably�� t�e Para — Forssman 
glycolipid is a natural cross-reactive ligand to antibodies�� 
w�ic� we named “anti-PFdi”�� because it contains a ter-
minated GalNAcβ�-3GalNAcβ disacc�aride�� t�e same 
as in PFdi-PAA [�8�� ��]. T�e serum anti-PFdi IgG did 
not react wit� t�e Forssman disacc�aride �GalNAcα�-
3GalNAcβ�� and ot�er ligands [3]. It is in agreement wit� 
vice versa investigations: t�e lack of t�e cross-reactivity 
between Forssman and Para — Forssman glycolipids was 
observed earlier for anti-Forssman antibodies [�8]. We 
did not find any literature data about t�e expression of 
t�e Para — Forssman antigen in �uman tissues�� except 
in eryt�rocytes�� w�ere it is present in low amounts [�8]. 
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Human natural anti-Para — Forssman antibodies ap-
peared to �ave been described earlier neit�er. W�et�er 
t�e Para — Forssman antigen is expressed in �uman 
gastric carcinoma similarly to t�e Forssman antigen 
remains to be clarified [��]. 
T�e natural ligand for anti-GalNAcβ antibodies 
may be glycolipid wit� a terminated GalNAcβ resi-
due�� for example GA��� an x� glycolipid or a P antigen. 
T�e serum anti-GalNAcβ IgG reacted weakly wit� Tn 
�GalNAcα�� and ot�er ligands [3]. T�e IgG antibodies 
affinity-purified on GalNAcβ-sep�arose from �uman 
serum were specific and did not s�ow any reactivity to 
Tn and t�e ot�er GalNAc-ligands tested earlier [3]�� but 
reacted weakly wit� synt�etic GA� �GalNAcβ�-4Galβ�-
4Glcβ�� �unpublis�ed observations��. T�e specificity of 
purified antibodies to PAA-glycoconjugates and t�eir 
reactivity to tumor-derived glycolipids�� as well as t�e 
c�aracterization of carbo�ydrate moiety wit� monoclo-
nal antibodies will be subjected to furt�er study. 
T�e exogenous origin of an antigenic stimulus 
s�ould not be neglected eit�er. A widespread �uman 
parasite Giardia intestinalis mig�t be related to t�e 
production of anti-PF antibodies because its cyst wall 
antigen contains t�e β��-3��-GalNAc-�omopolymer 
[��]. Alt�oug� t�e polymer is �ig�ly insoluble�� its de-
graded products �oligomers���� if t�ey form�� could be 
potential immunogens. 
T�e Helicobacter pylori infection is one of t�e 
main reasons for gastric disorders and its relation to 
cancer is well documented [��]. T�ere is evidence 
t�at t�e cancer-related TF-epitope is expressed in 
surface membrane glycoconjugates of H. pylori and 
is associated wit� a modulation of t�e natural immune 
response to a TF-antigen in infected subjects [�3]. No 
correlation or only a tendency to correlation between 
t�e levels of anti-GalNAcβ or anti-PFdi IgG and serum 
IgG antibodies against H. pylori cell surface antigens 
was observed in donors and cancer patients. T�e treat-
ment of H. pylori-infected patients wit� gastric ulcer 
�a standard one-week triple t�erapy�� did not influence 
t�e level of antibodies�� irrespective of t�e efficacy of 
t�erapy. T�e origin of immunogens remains unclear 
and needs furt�er exploration.
T�us�� significant differences in antibody levels 
were found owing to t�e application of t�e �ig�ly 
reproducible immunoassay wit� synt�etic �omoge-
neous neoantigens. T�e �ig� anti-PFdi antibody level 
in patients and its association wit� advanced cancer 
as well as prolonged postoperative c�anges during 
t�e follow-up suggest t�e presence of adaptive antibo-
dies t�at are involved in tumor pat�ogenesis directly 
or indirectly. A furt�er monitoring of patients and t�e 
survival analysis are now underway to evaluate t�e 
prognostic significance of antibodies.
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Соотношение между уРоВнем IgG �нтите�� �� G   alNAc бет� 
и диС�Х�Риду П�Р� — ФоРСм�нн� В СЫВоРот��е ��РоВи 
и ПРоГРеССиеЙ, � т���же СтеПенью диФФеРенциРоВ��и 
оПуХо��еЙ же��удоЧно-��ишеЧноГо тР���т�
В сыворотке крови человека ранее выявлены IgG-антитела к ��лево�оро�ны�� ли�ан�а�� GalNAcβ и GalNAcβ1-3GalNAcβ       
(�исахари� Пара — Форс��анна, PFdi). Цель иссле�ования — выяснение связи повышенно�о �ровня антител с про�рессией 
и �истоло�ически��и особенностя��и оп�холей жел��очно-кишечно�о тракта. Методы: обсле�овали 159 больных рако�� 
жел��ка, 88 — рако�� кишечника и 96 з�оровых лю�ей — �оноров крови. Уровень специфических IgG-антител опре�еляли  
��ето�о�� ИФА с использование�� синтетических конъю�атов полиакрила��и�а (ПАА), GalNAcβ-ПАА и PFdi-ПАА. �пре�еление    
биохи��ических и �е��атоло�ических показателей прово�или с использование�� авто��атических анализаторов. Результаты: 
�ровень анти-PFdi IgG � пациентов со злокачественны��и новообразования��и в ста�иях II–IV (          P = 0,0002 – 0,04) �остоверно 
выше, че�� � �оноров. Повышенный �ро вень анти-PFdi IgG ассоциировался с про�рессией рака жел��ка (в ста�иях II–IV по           
сравнению со ста�ией I ( P = 0,004 – 0,06) и �величение�� раз��ера оп�холи (T2 + T3 по сравнению с T1, ста�ии I, II;          P = 0.03). 
Различия в �ровнях анти-GalNAcβ IgG незначительные. �е выявлено взаи��освязи ��еж�� �ровне�� антител и ��етастазиро-         
вание�� оп�холей жел��ка и кишечника. Более низкий �ровень анти-GalNAcβ IgG опре�еляли � больных с ��енее �ифферен-      
цированны��и оп�холя��и (P = 0,01 – 0,04). В перио� послеоперационно�о наблю�ения от��ечали из��енения �ровня обоих 
типов антител. После хир�р�ическо�о ��аления оп�холей ор�анов жел��очно-кишечно�о тракта (ста�ия �ифференцировки 
G3) повышался �ровень как анти-PFdi IgG, так и анти-GalNAc        β IgG ( P = 0,003 – 0,01). Уровень анти-PFdi IgG коррелировал   
с �ровне�� С-реактивно�о белка (r = 0,50, P = 0,003), а �ровень анти-GalNAcβ IgG — с относительны�� количество�� ��оно-      
цитов в периферической крови (r = 0,42, P = 0,002). Выводы: �становлена зависи��ость �ровня анти-PFdi IgG от оп�холевой    
про�рессии, что по�тверж�ает их �частие в пато�енезе злокачественных новообразований ор�анов жел��очно-кишечно�о 
тракта. �еобхо�и��ы �альнейшие иссле�ования по опре�елению приро�ных ��ишеней �ля антител, роли в развитии �р��их 
заболеваний и про�ностическо�� значении при онколо�ической патоло�ии.
Ключевые слова: GalNAc бета1-3GalNAc бета, Пара — Форс��анн, полиакрила��и�-�ликоконъю�аты, IgG антитела, рак          
жел��ка, рак кишечника.
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